SCHEMBL18005252

SCHEMBL18005252

N#Cc1[nH]nnc1-c1nc(-c2ccc(C(F)(F)F)cc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ LTA4H P09960 1/20 0.44
▸ ATP4A P20648 3/20 0.42
▸ ATP4B P51164 3/20 0.42
▸ CDC25A P30304 1/20 0.40
▸ CDC25B P30305 1/20 0.40
▸ CDC25C P30307 1/20 0.40
▸ KIT P10721 1/20 0.39
▸ MYC P01106 1/20 0.39
▸ WDR5 P61964 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ GSTO1 P78417 1/20 0.37
▸ AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18004999 0.91 KDM4E (0.43) KDM4EL3MBTL1MEN1KMT2ANPSR1
SCHEMBL16398838 0.85 ALOX5 (0.42) KDM4EMEN1KMT2AATP4AATP4B
SCHEMBL18005195 0.84 RAB9A (0.49) KDM4EL3MBTL1MEN1KMT2ALTA4H
SCHEMBL18005011 0.81 CTSS (0.39) KDM4EL3MBTL1MEN1KMT2ANPSR1
SCHEMBL18005089 0.81 ALDH1A1 (0.39) KDM4EL3MBTL1MEN1KMT2ANPSR1
SCHEMBL18005021 0.80 EIF4E (0.41) KDM4EL3MBTL1MEN1KMT2ANPSR1
SCHEMBL16399311 0.80 ALDH1A1 (0.48) KDM4EMEN1KMT2ALTA4HCTSS
SCHEMBL18005028 0.80 MPL (0.37) KDM4EL3MBTL1MEN1KMT2ANPSR1
SCHEMBL1250478 0.79 KIF11 (0.50) MYCWDR5CTSSCTSKKIF11
SCHEMBL18005117 0.78 ABL1 (0.42) KDM4EMEN1KMT2AALDH1A1EIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KDM4E 2681/4885L3MBTL1 1503/4885MEN1 3151/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KDM4E 2681/4885L3MBTL1 1503/4885MEN1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback